title: Reduced cholesterol levels impair Smoothened activation in Smith-Lemli-Opitz syndrome.
abstract: Smith-Lemli-Opitz syndrome (SLOS) is a common autosomal-recessive disorder that results from mutations in the gene encoding the cholesterol biosynthetic enzyme 7-dehydrocholesterol reductase (DHCR7). Impaired DHCR7 function is associated with a spectrum of congenital malformations, intellectual impairment, epileptiform activity and autism spectrum disorder. Biochemically, there is a deficit in cholesterol and an accumulation of its metabolic precursor 7-dehydrocholesterol (7DHC) in developing tissues. Morphological abnormalities in SLOS resemble those seen in congenital Sonic Hedgehog (SHH)-deficient conditions, leading to the proposal that the pathogenesis of SLOS is mediated by aberrant SHH signalling. SHH signalling is transduced through the transmembrane protein Smoothened (SMO), which localizes to the primary cilium of a cell on activation and is both positively and negatively regulated by sterol molecules derived from cholesterol biosynthesis. One proposed mechanism of SLOS involves SMO dysregulation by altered sterol levels, but the salient sterol species has not been identified. Here, we clarify the relationship between disrupted cholesterol metabolism and reduced SHH signalling in SLOS by modelling the disorder in vitro. Our results indicate that a deficit in cholesterol, as opposed to an accumulation of 7DHC, impairs SMO activation and its localization to the primary cilium.
authors.affiliation: The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK.
authors.forename: Robert
authors.initials: R
authors.lastname: Blassberg
authors.affiliation: The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK.
authors.forename: James I
authors.initials: JI
authors.lastname: Macrae
authors.affiliation: The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK.
authors.forename: James
authors.initials: J
authors.lastname: Briscoe
authors.affiliation: Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Level 6, West Wing, Oxford OX3 9DU, UK, Department of Neurology, Milton Keynes Hospital, Standing Way, Milton Keynes, Buckinghamshire MK6 5LD, UK and Department of Neurology, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK john.jacob@ndcn.ox.ac.uk.
authors.forename: John
authors.initials: J
authors.lastname: Jacob
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism*; D003684:Dehydrocholesterols / Q000378:metabolism; D006801:Humans; D051379:Mice; D009154:Mutation; D041681:NIH 3T3 Cells; D010088:Oxidoreductases / Q000235:genetics / Q000378:metabolism; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D019082:Smith-Lemli-Opitz Syndrome / Q000235:genetics / Q000378:metabolism*; D000072086:Smoothened Receptor / Q000235:genetics / Q000378:metabolism*
chemical_list: D003684:Dehydrocholesterols; C491023:SMO protein, human; D000072086:Smoothened Receptor; D002784:Cholesterol; C016705:7-dehydrocholesterol; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; C078268:cholesterol reductase; C019995:7-dehydrocholesterol reductase